Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...

1 National University of Singapore Centre for Biomedical Ethics, Singapore 2 Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Semaglutide, ...

In a single-dose vial presentation Eli Lilly, a pharmaceutical firm has announced the launch of Mounjaro, following the authorization from the Central Drugs Standard Control Organization (CDSCO). The ...

New Delhi [India], March 20 (ANI): Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough drug for the treatment of Type 2 ...

Eli Lilly and Company launched Mounjaro in single-dose vial presentation following the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). It is a first-of-its-kind ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

CHICAGO, March 17, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...